PIRATE project: Point-of-care, informatics-based randomised controlled trial for decreasing overuse of antibiotic therapy in Gram-negative bacteraemia

BMJ Open

Volumn 7, Issue 7, 2017, Pages

  Huttner, Angela ^a   Albrich, Werner C ^b   Bochud, Pierre Yves ^c   Gayet Ageron, Angèle ^a   Rossel, Anne ^a   Von Dach, Elodie ^a   Harbarth, Stephan ^a   Kaiser, Laurent ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antibiotic Therapy; Bacteraemia; Duration; Gram negative; Point of care Randomization

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GRAM NEGATIVE SEPSIS; HOSPITAL PATIENT; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; POINT OF CARE TESTING; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; BACTEREMIA; CLINICAL TRIAL; CROSS INFECTION; DRUG EFFECTS; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; MALE; MEDICATION OVERUSE; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; POINT OF CARE SYSTEM; REGRESSION ANALYSIS; SWITZERLAND; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; C-REACTIVE PROTEIN; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POINT-OF-CARE SYSTEMS; PRESCRIPTION DRUG OVERUSE; REGRESSION ANALYSIS; SWITZERLAND; YOUNG ADULT;

EID: 85024394647     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2017-017996     Document Type: Article

References (41)

1. Huttner A, Harbarth S, Carlet J, et al. Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum. Antimicrob Resist Infect Control 2013;2:31.
2. WHO Antimicrobial Fact Sheet. 2015 http://www.who.int/mediacentre/factsheets/fs194/en/.
3. Swiss Federal Office of Public Health: responses to the antimicrobial resistance threat. 2015 http://www.bag.admin.ch/themen/internationales/11287/.
4. Holmes AH, Moore LS, Sundsfjord A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet 2016;387:176-87.
5. Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011;17:1798-803.
6. Chastre J, Wolff M, Fagon JY, et al. PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290:2588-98.
7. Havey TC, Fowler RA, Daneman N. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. Crit Care 2011;15:R267.
8. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49:1-45.
9. Sandberg T, Skoog G, Hermansson AB, et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, noninferiority trial. Lancet 2012;380:484-90.
10. Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004;54:515-23.
11. File TM, Mandell LA, Tillotson G, et al. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother 2007;60:112-20.
12. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752-60.
13. Runyon BA, McHutchison JG, Antillon MR, et al. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology 1991;100:1737-42.
14. Chaudry ZI, Nisar S, Ahmed U. Short course of antibiotic treatment in spontaneous bacterial peritonitis: a randomized controlled study. Journal of the College of Physicians and Surgeons Pakistan 2000;10:284-8.
15. Hepburn MJ, Dooley DP, Skidmore PJ, et al. Comparison of shortcourse (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004;164:1669-74.
16. Oliveira CF, Botoni FA, Oliveira CR, et al. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Crit Care Med 2013;41:2336-43.
17. Adamina M, Steffen T, Tarantino I, et al. Meta-analysis of the predictive value of C-reactive protein for infectious complications in abdominal surgery. Br J Surg 2015;102:590-8.
18. Lin KH, Wang FL, Wu MS, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection in patients with liver cirrhosis: a systematic review and meta-analysis. Diagn Microbiol Infect Dis 2014;80:72-8.
19. Torres A, Ramirez P, Montull B, et al. Biomarkers and communityacquired pneumonia: tailoring management with biological data. Semin Respir Crit Care Med 2012;33:266-71.
20. Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008;177:498-505.
21. Wacker C, Prkno A, Brunkhorst FM, et al. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013;13:426-35.
22. Uçkay I, Garzoni C, Ferry T, et al. Postoperative serum pro-calcitonin and C-reactive protein levels in patients with orthopedic infections. Swiss Med Wkly 2010;140:w13124.
23. Havey TC, Fowler RA, Pinto R, et al. Duration of antibiotic therapy for critically ill patients with bloodstream infections: A retrospective cohort study. Can J Infect Dis Med Microbiol 2013;24:129-37.
24. Corona A, Wilson AP, Grassi M, et al. Prospective audit of bacteraemia management in a university hospital ICU using a general strategy of short-course monotherapy. J Antimicrob Chemother 2004;54:809-17.
25. Bouadma L, Luyt CE, Tubach F, et al. PRORATA trial group. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375:463-74.
26. de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, openlabel trial. Lancet Infect Dis 2016;16:819-27.
27. Albrich WC, Harbarth S. Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting. Intensive Care Med 2015;41:1739-51.
28. Schuetz P, Briel M, Christ-Crain M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 2012;55:651-62.
29. Reinhart K, Bauer M, Riedemann NC, et al. New approaches to Sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev 2012;25:609-34.
30. Fitzpatrick JM, Biswas JS, Edgeworth JD, et al. Gram-negative bacteraemia; a multi-centre prospective evaluation of empiric antibiotic therapy and outcome in English acute hospitals. Clin Microbiol Infect 2016;22:244-51.
31. Angus DC, Seymour CW, Coopersmith CM, et al. A framework for the Development and Interpretation of Different Sepsis definitions and clinical criteria. Crit Care Med 2016;44:e113-e121.
32. Pittet D, Li N, Wenzel RP. Association of secondary and polymicrobial nosocomial bloodstream infections with higher mortality. Eur J Clin Microbiol Infect Dis 1993;12:813-9.
33. Detry MA, Lewis RJ. The intention-to-treat principle: how to assess the true effect of choosing a medical treatment. JAMA 2014;312:85-6.
34. Food & Drug Administration. Guidance for Industry. E9 Statistical Principles for Clinical Trials 1998 http://www.fda.gov/downloads/drugs/./guidances/ucm073137.pdf.
35. Chenaud C, Merlani P, Luyasu S, et al. Informed consent for research obtained during the intensive care unit stay. Crit Care 2006;10:R170.
36. Paul M, Bronstein E, Yahav D, et al. External validity of a randomised controlled trial on the treatment of severe infections caused by MRSA. BMJ Open 2015;5:e008838.
37. Balajonda N, Bisanar TL, Mathew JP, et al. Determinants of a subject's decision to participate in clinical anesthesia research. Anesth Analg 2013;116:448-54.
38. Gayet-Ageron A, Rudaz S, Perneger T. Biobank attributes associated with higher patient participation: a randomized study. Eur J Hum Genet 2016;25:31-6.
39. Knoester PD, Belitser SV, Deckers CL, et al. Recruitment of a cohort of lamotrigine users through community pharmacists: differences between patients who gave informed consent and those who did not. Pharmacoepidemiol Drug Saf 2005;14:107-12.
40. Beebe TJ, Ziegenfuss JY, Jenkins SM, et al. Who doesn't authorize the linking of survey and administrative health data? A general population-based investigation. Ann Epidemiol 2011;21:706-9.
41. Huang N, Shih SF, Chang HY, et al. Record linkage research and informed consent: who consents? BMC Health Serv Res 2007;7:18.